A director at Texas Pacific Land Corp bought 12 shares at 1,376.900USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Moody's Ratings has completed a periodic review of the ratings of Continental Resources, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 14 March 2024 in which Moody's reassessed the appropriateness of the ratings in the conte...
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including ...
Das Leitprojekt HDP-101 zeigte bisher Sicherheit und gute Verträglichkeit; umso mehr überraschte der ATAC-Wirkstoff MGTA-117 vom Partner Magenta mit einer dosislimitierenden Toxizität in seiner dritten Patientenkohorte (CN vom 25.01.23). Die klinische Ph 1/2-Studie bei Magenta wurde ausgesetzt. Interessanterweise wurden alle Projekte dort eingestellt, auch diejenigen ohne Bezug zu ATAC®. Magenta prüft nun „alle strategischen Optionen“. Nach eigener Aussage des Heidelberg Pharma Managements lieg...
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.